Tao Fu has been a member of our Board of Directors since 2017, and our President & Chief Operating Officer since September 2018.  Prior to joining Zai Lab, he worked at Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company's corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company and Becton Dickinson.

Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).

Professor Chen has been our independent director since August 2018. He has more than 55 years of academic and administrative experience. He was first elected as a member of the Chinese Academy of Sciences (CAS) in 1999 and served as President of the Shanghai Science and Technology Association in 2011. Prof. Chen served as the Principal Scientist for two National Basic Research Programs (commonly known as the 973 Program) administered by the PRC Ministry of Science and Technology (MOST). In 2001, he served as a key architect for the "Innovative Drug and Modernization of Chinese Medicines" initiative of MOST, which is generally recognized as one of the highest impact programs undertaken to date by MOST. As an architect for this program, Prof. Chen organized and promoted a series of innovative drug policies for the Chinese government's 12th and 13th Five-Year Plans. Prof. Chen also served as a member of the National Committee of Chinese People's Political Consultative Conference (CPPCC) from 2007 to 2017.

Prof. Chen started his academic career in 1985 when he joined the Shanghai Institute of Materia Medica (SIMM) as an Associate Professor, where he was promoted to Full Professor in 1990. From 1993 to 1996, he served as Deputy Director of SIMM. From 1996 to 2004, he served as Director of SIMM. From 2005 to 2014, Prof. Chen served as President of Shanghai University of Traditional Chinese Medicine.

Prof. Chen graduated with a chemistry degree from Fudan University in 1967. He received his M.Phil. and Ph.D. degrees at SIMM and CAS, in 1982 and 1985, respectively. From 1985 to 1988, he conducted postdoctoral research at Institut de Biologie Physico-Chimique in Paris, France. Prof. Chen has published more than 200 papers in academic journals worldwide.

William Lis has been our independent director since October 2018. He has 27 years of biopharmaceutical experience. He served as Chief Executive Officer and a Director of Portola Pharmaceuticals, Inc. from 2010 until 2018 after serving as Chief Operating Officer and Chief Business Officer in 2009 and 2008. Under his leadership, Portola successfully grew from a discovery stage company to a fully integrated R&D and commercial organization, and independently advanced: Andexxa® and Bevyxxa® that received FDA Breakthrough and Fast Track designation respectively, from discovery and early stage development through commercial launch; cerdulatinib, a novel immunology and oncology compound, from discovery through phase 2. He led private and public financings totaling $1b, including an initial public offering in 2013; multiple corporate partnerships; academic clinical development collaborations; and oversaw the execution of milestones that resulted in the growth of the company’s valuation from $250 million to $2.7 billion during his tenure.

Prior to Portola, Mr. Lis held executive and management positions at Scios, Inc. (a Johnson & Johnson company) from 2003 to 2008 where he last served as Vice President of Commercial Operations and Business Development, having led efforts for the in-licensing, and then the strategic development and pre-commercial launch for Xarelto®; and served on the Janssen West Coast Research and Development Committee. He also held positions of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) from 1998 to 2003 in sales, marketing, and medical affairs for the launch and commercialization of INTEGRILIN® and project management and business development for early stage compounds. Earlier in his career, he was involved in the U.S. commercial launch of several products with multiple pharmaceutical companies, including Lovenox® and Rilutek® while at Rhone-Poulenc Rorer.

Mr. Lis served as a member of the Bio Board of Directors, Emerging Companies Section in 2015 and 2016.

Mr. Lis holds a B.S. from the University of Maryland.

Richard A. Flavell, PhD, FRS, has served on our Scientific AdvisoryBoard since 2017. Since 2002, Dr. Flavell has been the Sterling Professor ofImmunobiology at Yale University School of Medicine. Prior to joining the Yalefaculty in 1988, Dr. Flavell was the President and Chief Scientific Officer ofBiogen Research Corporation.

Dr. Flavell received a Ph.D. in biochemistry from the Universityof Hull, England, and performed postdoctoral work in Amsterdam and Zurich. Heis an Investigator of the Howard Hughes Medical Institute, a fellow of theRoyal Society, a member of the National Academy of Sciences, and a member ofthe Institute of Medicine of the National Academies. He has published over 800papers and has received many awards, including the Invitrogen MeritoriousCareer Award from the American Association of Immunologists.

Neal Rosen, MD, PhD, has served on our scientific advisory board since 2016. Dr. Rosen is a Member of the Department of Medicine and a Member of the Molecular Pharmacology and Chemistry Program at Memorial Sloan Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School. He has played an important role in the development of tyrosine kinase-mediated signaling inhibitors and has pioneered the concept that cancer cells are dependent on cellular machinery for protein folding.

Dr. Rosen received a medical degree and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Women’s Hospital and post-doctoral training and a fellowship in Medical Oncology at the National Cancer Institute, where he served on the senior staff prior to joining the faculty of Memorial Sloan Kettering Cancer Center. He was the recipient of the NIH/NCI Outstanding Investigator Award in 2016.